AACE Rare Endocrine Disease Series On Demand: Are these Changes in my Health Significant? Identifying and Treating Cushing’s Syndrome
CME
1
|
ABIM MOC
1
|
Nursing
1
on demand banner

AACE Rare Endocrine Disease Series is pleased to present Are these Changes in my Health Significant? Identifying and Treating Cushing’s Syndrome, a course designed to help clinicians create a path to diagnosis when encountering a patient with Cushing's Syndrome.  

This disease was chosen due to its rarity, symptom complexity, and need for improved diagnostic and management strategies. The course will provide clinicians with the latest evidence-based guidelines, algorithms, consensus statements, and educational resources for diagnosing, managing, and treating these conditions. By highlighting the latest research and clinical advances, AACE aims to increase clinicians’ awareness, knowledge, and competence, ultimately improving the quality of care and outcomes for patients with this rare endocrine disease.   

1
CME
Starts

10/14/2024

Expires

10/14/2025

Learning Objectives

Upon completion of the program, participants will be able to:

  • Describe the diagnostic and testing approach in evaluating a patient with cushing's syndrome.  
  • Utilize evidence-based guidelines, algorithms, and consensus statements to diagnose and treat cushing's syndrome.  
  • Identify and treat long-term complications and comorbidities of cushing's syndrome.  
Target Audience

Endocrinologists

Accreditation and Designation Statements

Physicians and Physician Assistants 
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.  

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared.

Nurses
American Association of Clinical Endocrinology is approved by the California Board of Registered Nursing, Provider Number 17762, for 1 contact hours.

Disclosures and Conflicts of Interest

Planner Disclosures

  • Ricardo Correa, MD, FACE: Centers for Disease Control and Prevention: Research Funding; Recordati: Research Funding; Moderna: Consultant
  • Kevin Yuen, MD, FACE: Ascendis: Research Funding, Consultant; Corcept: Research Funding; Chiesi: Research Funding, Consultant; Crinetics: Research Funding, Consultant; Neurocrine: Consultant; Novo Nordisk: Speakers’ Bureau, Consultant; Recordati: Speakers’ Bureau, Consultant; Sparrow: Research Funding
  • Susan Samson, MD, PhD, FACE: Amryt: Consultant; Chiasma: Consultant; Chiesi: Consultant, Recordati: Consultant
  • Shobana Athimulam, MD: No relationships to disclose
  • Chris Yedinak, DNP: No relationships to disclose
  • Amy Ogunsunlade: No relationships to disclose

Speaker Disclosures

  • Ricardo Correa, MD, FACE: Centers for Disease Control and Prevention: Research Funding; Recordati: Research Funding; Moderna: Consultant
  • Shobana Athimulam, MD: No relationships to disclose 
  • Chris Yedinak, DNP: No relationships to disclose 
     

All of the relevant financial relationships listed for these individuals have been mitigated.

Commercial Support

This activity is supported by an educational grant from Corcept Therapeutics and Xeris Pharmaceutical.